Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to severe Palmoplantar Pustulosis (PPP)

Administered By

Awarded By

Contributors

Start/End

  • September 24, 2019 - April 20, 2021